MPS VI Clinical Surveillance Program (CSP)
Latest Information Update: 06 Nov 2021
At a glance
- Drugs Galsulfase (Primary)
- Indications Mucopolysaccharidosis VI
- Focus Adverse reactions; Therapeutic Use
- Acronyms MPS VI CSP
- Sponsors BioMarin Pharmaceutical
- 02 Apr 2021 Status changed from recruiting to completed.
- 30 Oct 2014 New source identified and integrated: United Kingdom Clinical Research Network record.
- 28 May 2014 New trial record